PMID- 19812032
OWN - NLM
STAT- MEDLINE
DCOM- 20100205
LR  - 20161202
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 284
IP  - 50
DP  - 2009 Dec 11
TI  - Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase
      polymerization, excision antagonism, and tenofovir resistance.
PG  - 35092-100
LID - 10.1074/jbc.M109.022525 [doi]
AB  - K65R is a primary reverse transcriptase (RT) mutation selected in human
      immunodeficiency virus type 1-infected patients taking antiretroviral regimens
      containing tenofovir disoproxil fumarate or other nucleoside analog RT drugs. We 
      determined the crystal structures of K65R mutant RT cross-linked to
      double-stranded DNA and in complexes with tenofovir diphosphate (TFV-DP) or dATP.
      The crystals permit substitution of TFV-DP with dATP at the dNTP-binding site.
      The guanidinium planes of the arginines K65R and Arg(72) were stacked to form a
      molecular platform that restricts the conformational adaptability of both of the 
      residues, which explains the negative effects of the K65R mutation on nucleotide 
      incorporation and on excision. Furthermore, the guanidinium planes of K65R and
      Arg(72) were stacked in two different rotameric conformations in TFV-DP- and
      dATP-bound structures that may help explain how K65R RT discriminates the drug
      from substrates. These K65R-mediated effects on RT structure and function help us
      to visualize the complex interaction with other key nucleotide RT drug resistance
      mutations, such as M184V, L74V, and thymidine analog resistance mutations.
FAU - Das, Kalyan
AU  - Das K
AD  - Center for Advanced Biotechnology and Medicine (CABM), Rutgers University,
      Piscataway, New Jersey 08854, USA.
FAU - Bandwar, Rajiv P
AU  - Bandwar RP
FAU - White, Kirsten L
AU  - White KL
FAU - Feng, Joy Y
AU  - Feng JY
FAU - Sarafianos, Stefan G
AU  - Sarafianos SG
FAU - Tuske, Steven
AU  - Tuske S
FAU - Tu, Xiongying
AU  - Tu X
FAU - Clark, Arthur D Jr
AU  - Clark AD Jr
FAU - Boyer, Paul L
AU  - Boyer PL
FAU - Hou, Xiaorong
AU  - Hou X
FAU - Gaffney, Barbara L
AU  - Gaffney BL
FAU - Jones, Roger A
AU  - Jones RA
FAU - Miller, Michael D
AU  - Miller MD
FAU - Hughes, Stephen H
AU  - Hughes SH
FAU - Arnold, Eddy
AU  - Arnold E
LA  - eng
SI  - PDB/3JSM
SI  - PDB/3JYT
GR  - P01 GM066671/GM/NIGMS NIH HHS/United States
GR  - Intramural NIH HHS/United States
GR  - AI 27690/AI/NIAID NIH HHS/United States
GR  - P01 GM 066671/GM/NIGMS NIH HHS/United States
GR  - R37 AI027690/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20091007
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Organophosphonates)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 94ZLA3W45F (Arginine)
RN  - 99YXE507IL (Tenofovir)
RN  - EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - JAC85A2161 (Adenine)
SB  - IM
MH  - Adenine/*analogs & derivatives/chemistry/pharmacology
MH  - Arginine/genetics/metabolism
MH  - Crystallization
MH  - Crystallography, X-Ray
MH  - Drug Resistance, Viral/*physiology
MH  - *HIV Reverse Transcriptase/chemistry/drug effects/physiology
MH  - Humans
MH  - Models, Molecular
MH  - Molecular Sequence Data
MH  - Molecular Structure
MH  - *Mutation
MH  - Organophosphonates/chemistry/*pharmacology
MH  - Protein Conformation
MH  - Reverse Transcriptase Inhibitors/chemistry/*pharmacology
MH  - Tenofovir
PMC - PMC2787370
OID - NLM: PMC2787370
EDAT- 2009/10/09 06:00
MHDA- 2010/02/06 06:00
CRDT- 2009/10/09 06:00
PHST- 2009/10/09 06:00 [entrez]
PHST- 2009/10/09 06:00 [pubmed]
PHST- 2010/02/06 06:00 [medline]
AID - M109.022525 [pii]
AID - 10.1074/jbc.M109.022525 [doi]
PST - ppublish
SO  - J Biol Chem. 2009 Dec 11;284(50):35092-100. doi: 10.1074/jbc.M109.022525. Epub
      2009 Oct 7.